| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 01/24/2002 | WO2002005786A1 Pharmaceutical composition improved in peroral absorbability |
| 01/24/2002 | WO2001078761A3 Mixture of defibrotide and g-csf ant its use for activating haematopoietic progenitors |
| 01/24/2002 | WO2001060412A3 Modification of biopolymers for improved drug delivery |
| 01/24/2002 | WO2001047506A3 Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments |
| 01/24/2002 | WO2001046258A3 Transporters and ion channels |
| 01/24/2002 | WO2001038305A3 Novel il-8 receptor antagonists |
| 01/24/2002 | WO2001034768A3 15 human secreted proteins |
| 01/24/2002 | WO2001032910A3 27 human secreted proteins |
| 01/24/2002 | WO2001027107A3 Heterocyclic sodium/proton exchange inhibitors and method |
| 01/24/2002 | WO2001025436A3 Endozepine-like polypeptides and polynucleotides encoding same |
| 01/24/2002 | WO2001023357A3 Fused cycloheptane and fused azacycloheptane compounds and their use as integrin receptor antagonists |
| 01/24/2002 | WO2001019860A3 Proteins associated with cell differentiation |
| 01/24/2002 | WO2001012819A3 Protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 01/24/2002 | WO2001000655A3 Therapeutic peptides derived from subsequences of bpi |
| 01/24/2002 | WO2000073478A9 Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration |
| 01/24/2002 | WO2000053168A3 Synergy between low molecular weight heparin and platelet aggregation inhibitors, for preventing and treating thromboembolic disorders |
| 01/24/2002 | US20020010344 Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade |
| 01/24/2002 | US20020010189 For treatment of sexual disorders, male erectile dysfunction |
| 01/24/2002 | US20020010185 Anticarcinogenic agents |
| 01/24/2002 | US20020010183 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors |
| 01/24/2002 | US20020010170 Pyrimido(1,6-b)pyridazine derivatives used as p38 inhibitors a mammalian protein kinase is involved in cell proliferation, cell death and response to extracellular stimuli |
| 01/24/2002 | US20020010158 Derivatives of 5-pyridylalkylphosphonates and 5-pyridylalkylmalonates useful drugs for treatment of cardiovascular related diseases and diabetes mellitus related diseases |
| 01/24/2002 | US20020010153 Oral delivery of macromolecules |
| 01/24/2002 | US20020010146 Nitrosated and nitrosylated taxanes, compositions and methods of use |
| 01/24/2002 | US20020009783 Aqueous solutions comprising a polysaccharide oncotic agent, a physiologically compatible buffer, a simple hexose sugar, dissolved chloride salt of sodium, calcium and magnesium and an organic acid or salt or ester, substitute for blood |
| 01/24/2002 | US20020009776 Fibroblast growth factor receptor-like molecules and uses thereof |
| 01/24/2002 | DE10034233A1 Tocotrienolchinon-Cyclisierungsprodukte Tocotrienolquinone cyclization products |
| 01/24/2002 | CA2416693A1 Phosphatonin-related gene and methods of use thereof |
| 01/24/2002 | CA2416384A1 Sulfone derivatives, their production and use |
| 01/24/2002 | CA2415932A1 Cyclic oxyguanidine pyrazinones as protease inhibitors |
| 01/24/2002 | CA2415673A1 Tetrazole derivatives |
| 01/24/2002 | CA2413582A1 Use of a spla2 inhibitor for the treatment of sepsis |
| 01/23/2002 | EP1174434A1 Phosphonic acid derivative having inhibitory activity against carboxypeptidase B |
| 01/23/2002 | EP1174421A1 3-amidinobenzenesulfonamide derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| 01/23/2002 | EP1173569A1 Synthetic signalling molecules |
| 01/23/2002 | EP1173566A2 Human membrane-associated proteins |
| 01/23/2002 | EP1173485A1 Human antibodies to staphylococcus aureus |
| 01/23/2002 | EP1173477A1 49 human secreted proteins |
| 01/23/2002 | EP1173468A1 Integrin receptor antagonists |
| 01/23/2002 | EP1173462A1 50 human secreted proteins |
| 01/23/2002 | EP1173186A1 Use of tagatose to enhance key blood factors |
| 01/23/2002 | EP1173183A2 Use of compounds with a nitrogen-oxygen heterocycle |
| 01/23/2002 | EP1173171A1 Novel anticoagulant injectable composition |
| 01/23/2002 | EP1173162A1 Compositions of boswellic acids derived from boswellia serrata gum resin, for treating lymphoproliferative and autoimmune conditions |
| 01/23/2002 | EP0941103B1 Pharmaceutical composition for treatment of diabetes |
| 01/23/2002 | EP0726771B1 Desferrioxamine oral delivery system |
| 01/23/2002 | CN1332737A Thrombin inhibitors |
| 01/23/2002 | CN1332734A Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity |
| 01/23/2002 | CN1332723A Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them |
| 01/23/2002 | CN1332646A Method for production of stroma-free hemoglobin |
| 01/23/2002 | CN1332645A Stent grafts with bioactive coatings |
| 01/23/2002 | CN1332626A Inhalation system |
| 01/23/2002 | CN1332242A Ahylysantinfarctase thrombase and its production process |
| 01/23/2002 | CN1332241A Ahylysantinfarctase thrombase and its production process |
| 01/23/2002 | CN1078070C Use of benzo-thiophone derivative in prep. of thrombin-inhibiting medicine |
| 01/22/2002 | US6340742 Erythropoietin conjugates |
| 01/22/2002 | US6340694 Diarylbenzopyran derivatives as cyclooxygenase-2 inhibitors |
| 01/22/2002 | US6340681 Useful as analgesics in mammals |
| 01/22/2002 | US6340675 Process for the production of an anticoagulant composition |
| 01/22/2002 | US6340668 Administering bone morphogenetic protein-11 (bmp-11) to neuronal cells effective to promote the survival of cells |
| 01/22/2002 | CA2149333C Eck receptor ligands |
| 01/22/2002 | CA2093794C 1'-aminospiro¬isoquinoline-4(1h),3-pyrrolidine|-1,2',3,5'-(2h)-tetrones and analogs thereof useful as aldose reductase inhibitors |
| 01/22/2002 | CA2051460C Pharmaceutical compounds |
| 01/22/2002 | CA2038848C Hydantoin derivatives |
| 01/17/2002 | WO2002004958A1 Method for determining potential alterations of a substance having biological activities |
| 01/17/2002 | WO2002004612A2 Drug metabolizing enzymes |
| 01/17/2002 | WO2002004461A1 Hydropyridine derivative acid addition salts |
| 01/17/2002 | WO2002004459A1 Modulators of protein tyrosine phosphatases (ptpases) |
| 01/17/2002 | WO2002004423A1 Thrombin inhibitors comprising an aminoisoquinoline group |
| 01/17/2002 | WO2002004421A2 Pyridoxine and pyridoxal analogues: cardiovascular therapeutics |
| 01/17/2002 | WO2002004412A2 Tyrosine derivatives as phosphatase inhibitors |
| 01/17/2002 | WO2002004067A1 Method and device for avoiding alteration of a substance having biological activities |
| 01/17/2002 | WO2002004031A1 Compositions and methods for treating cardiovascular disorders |
| 01/17/2002 | WO2002004025A1 Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| 01/17/2002 | WO2002004010A2 Inhibition of tumor growth by a nematode anticoagulant protein |
| 01/17/2002 | WO2002004008A2 Methods of therapy with thrombin derived peptides |
| 01/17/2002 | WO2002004002A2 Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals |
| 01/17/2002 | WO2002003991A2 Use of substituted indole compounds for increasing nitric oxide synthase activity |
| 01/17/2002 | WO2002003972A2 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds |
| 01/17/2002 | WO2002003960A1 Particulate vectors for improving oral absorption of active principles |
| 01/17/2002 | WO2001043765A3 Method for localized administration of fibrinolytic metalloproteinases |
| 01/17/2002 | WO2001034175A3 Methods of treating inflammatory bowel disease using cholera toxin b subunit |
| 01/17/2002 | WO2001030997A3 Microbe, microbial exopolysaccharide, and uses thereof |
| 01/17/2002 | WO2001030996A3 Microbial exopolysaccharide and uses thereof |
| 01/17/2002 | WO2001027623A3 Isoagglutinin-depleted blood compositions and methods of making same |
| 01/17/2002 | WO2001021259A3 Use and compositions for treating platelet-related disorders using anagrelide |
| 01/17/2002 | WO2001007471A3 Cell cycle and proliferation proteins |
| 01/17/2002 | WO2000078953A3 Human transport proteins |
| 01/17/2002 | WO2000078952A3 Human rna metabolism proteins (rmep) |
| 01/17/2002 | WO2000071493A3 INHIBITORS OF FACTOR Xa |
| 01/17/2002 | US20020007141 Method of removing thrombosis in fistulae |
| 01/17/2002 | US20020007070 For inhibiting loss of blood platelets; inhibiting formation of blood platelet aggregates, fibrin, thrombus, and embolus; anticoagulants embedded in devices for blood collection, circulation, storage (catheters, dialysis machines); stents |
| 01/17/2002 | US20020006923 Thrombin inhibitors |
| 01/17/2002 | US20020006917 Method of locking 1alpha-OH of vitamin D compounds in axial orientation |
| 01/17/2002 | US20020006640 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 01/17/2002 | CA2415778A1 Methods of therapy with thrombin derived peptides |
| 01/17/2002 | CA2415624A1 Compositions and methods for treating cardiovascular disorders |
| 01/17/2002 | CA2414387A1 Drug metabolizing enzymes |
| 01/17/2002 | CA2414188A1 Pyridoxine and pyridoxal analogues: cardiovascular therapeutics |
| 01/17/2002 | CA2414111A1 Use of substituted indole compounds for increasing nitric oxide synthase activity |